Aethlon Medical Signs Cooperative Research and Development Agreement with The U.S. Army Medical Research Institute of Infectious Diseases.

SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD), announced today that it has executed a Cooperative Research and Development Agreement (CRADA) with The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The focus of the agreement is to explore the therapeutic efficacy of the Aethlon Hemopurifier[R] against viral hemorrhagic fever (VHF) targets, including, but not limited to Ebola Virus, Marburg Virus, Lassa Virus, and Machupo Virus.

About USAMRIID

USAMRIID, located at Fort Detrick, Maryland, is the lead laboratory for the Medical Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command. The Institute plays a key role as the only laboratory in the Department of Defense (DOD) equipped to study Ebola and other highly hazardous infectious agents requiring maximum containment at bio-safety level four (BSL-4). The information contained in this press release does not necessarily reflect the position or the policy of the government and no official endorsement should be inferred.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier[R], a first-in-class medical device to treat infectious disease. The Hemopurifier[R] is an innovative platform technology targeted to be a broad-spectrum treatment solution for drug- and vaccine-resistant bioweapons, naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Collaborative studies to demonstrate utility of the Hemopurifier[R] are being conducted with researchers at the Government of India's National Institute of Virology (NIV), The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Aethlon has previously demonstrated the safety of the Hemopurifier[R] in a 24-treatment human study, and most recently submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) requesting permission to initiate human studies of the Hemopurifier[R] as a treatment countermeasure against select category "A" bioterror threats. Category "A" threats are defined by the CDC as agents that pose a risk to national security; are easily disseminated or transmitted from person to person; result in high mortality rates; may cause public panic and social disruption; and require special action for public health preparedness. Additional information on Aethlon Medical and its Hemopurifier[R] technology can be accessed at www.aethlonmedical.com.

The information contained in this press release does not necessarily reflect the position or the policy of the government and no official endorsement should be inferred. Certain of the statements herein may be forward looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc., to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.